30

ApicHope Pharmaceutical Co LtdSHE 300723 Stock Report

Last reporting period 30 Sep, 2023

Updated 29 Oct, 2024

Last price

Market cap $B

0.559

Micro

Exchange

XSHE - Shenzhen Stock Exchange

300723.SZ Stock Analysis

30

Avoid

Based on Eyestock quantitative analysis, 300723.SZ`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

47/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

39.0 %

Greatly undervalued

Market cap $B

0.559

Dividend yield

0.93 %

Shares outstanding

280.95 B

ApicHope Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of chemical medicine, traditional Chinese medicine products, and biological vaccines. The company is headquartered in Guangzhou, Guangdong and currently employs 1,079 full-time employees. The company went IPO on 2017-11-16. The firm has two types of products which are children's drugs and chronic disease drugs. The children's drugs are used for the treatment of colds, digestive anorexia, viral infections, children's eczema and other diseases, including clindamycin palmitate dispersible tablets and clindamycin palmitate granules. The chronic disease drugs include hepatocyte growth-promoting hormone for injection, aceglutamine for injection and adenosine cyclophosphate for injection, which are used for the treatment of severe viral hepatitis and cardiovascular and cerebrovascular diseases. The firm is also engaged in selling drugs for agents.

View Section: Eyestock Rating